BIOCON - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 2.7
| Stock Code | BIOCON | Market Cap | 59,785 Cr. | Current Price | 369 ₹ | High / Low | 425 ₹ |
| Stock P/E | 307 | Book Value | 120 ₹ | Dividend Yield | 0.14 % | ROCE | 2.09 % |
| ROE | 0.40 % | Face Value | 5.00 ₹ | DMA 50 | 382 ₹ | DMA 200 | 372 ₹ |
| Chg in FII Hold | 0.53 % | Chg in DII Hold | 2.07 % | PAT Qtr | 111 Cr. | PAT Prev Qtr | 70.9 Cr. |
| RSI | 38.2 | MACD | -0.43 | Volume | 20,42,265 | Avg Vol 1Wk | 30,48,094 |
| Low price | 295 ₹ | High price | 425 ₹ | PEG Ratio | -16.5 | Debt to equity | 0.16 |
| 52w Index | 56.5 % | Qtr Profit Var | 3,183 % | EPS | 0.07 ₹ | Industry PE | 27.2 |
Analysis: Biocon Ltd (BIOCON) is not an ideal candidate for swing trading due to weak fundamentals and technical signals. At ₹369, the stock is trading below both its 50 DMA (₹382) and 200 DMA (₹372), reflecting bearish sentiment. RSI at 38.2 suggests near oversold conditions, while MACD at -0.43 confirms weak momentum. The P/E of 307 is extremely high compared to the industry average of 27.2, indicating severe overvaluation. ROCE (2.09%) and ROE (0.40%) are very low, showing poor efficiency. Despite a sharp quarterly profit jump (+3,183%), EPS remains negligible (₹0.07), raising sustainability concerns. Swing trade potential is limited and risky.
Optimal Entry Price: Around ₹355–₹365, closer to support levels, only for short-term rebound trades.
Exit Strategy (if already holding): Consider exiting near ₹385–₹395, where resistance aligns with the 50 DMA. A stop-loss near ₹350 is advisable to manage downside risk.
✅ Positive
- Quarterly PAT growth from ₹70.9 Cr. to ₹111 Cr. (+3,183%).
- DII holdings increased (+2.07%), showing domestic institutional support.
- FII holdings also increased slightly (+0.53%).
- 52-week index performance (+56.5%) shows resilience despite weak fundamentals.
⚠️ Limitation
- Extremely high P/E of 307 vs industry 27.2.
- Weak ROCE (2.09%) and ROE (0.40%).
- EPS of only ₹0.07, reflecting poor earnings power.
- Stock trading below both 50 & 200 DMA.
📰 Company Negative News
- MACD remains negative, signaling weak momentum.
- Low dividend yield (0.14%) offers little investor return.
🌟 Company Positive News
- Quarterly profit growth (+3,183%) shows short-term earnings recovery.
- Institutional support from both FII and DII holdings.
- Strong 52-week index performance (+56.5%).
🏭 Industry
- Biopharma sector has long-term growth potential driven by healthcare demand.
- Industry P/E at 27.2 indicates moderate valuations compared to Biocon’s extreme premium pricing.
📌 Conclusion
Biocon is fundamentally weak with poor efficiency metrics and extreme overvaluation. While short-term profit growth and institutional support provide positives, technical indicators remain bearish. Entry near ₹355–₹365 may be considered for a short-term rebound, with exit around ₹385–₹395. Overall, swing trade potential is limited and caution is strongly advised.